Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-107301
Filing Date
2025-08-12
Accepted
2025-08-12 16:06:34
Documents
61
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q antx-20250630.htm   iXBRL 10-Q 2553109
2 EX-10.1 antx-ex10_1.htm EX-10.1 41928
3 EX-31.1 antx-ex31_1.htm EX-31.1 18732
4 EX-31.2 antx-ex31_2.htm EX-31.2 19045
5 EX-32.1 antx-ex32_1.htm EX-32.1 9080
6 EX-32.2 antx-ex32_2.htm EX-32.2 8880
  Complete submission text file 0000950170-25-107301.txt   8353682

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT antx-20250630.xsd EX-101.SCH 1005699
64 EXTRACTED XBRL INSTANCE DOCUMENT antx-20250630_htm.xml XML 1364545
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

EIN.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41331 | Film No.: 251206655
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)